
    
The genomic variant c.2558G>A p.Arg853Gln, designated as rs794727152, is located on the SCN2A gene, which encodes the NaV1.2 voltage-gated sodium channel. This channel is predominantly expressed in excitatory neurons and plays a critical role in the initiation and propagation of action potentials, thus being essential for neuronal excitability and communication.The p.Arg853Gln variant has been associated with a range of neurodevelopmental disorders, including developmental and epileptic encephalopathies (DEE) and autism spectrum disorders (ASD). This missense variant results in the substitution of arginine to glutamine at position 853 of the NaV1.2 channel, which is a highly conserved amino acid residue within the helical repeat II region of the protein, suggesting its functional importance [2].Functional studies have demonstrated that the p.Arg853Gln variant leads to a loss-of-function effect on the NaV1.2 channel. Specifically, the variant has been shown to cause an overall reduction in channel function due to multiple defects in time- and voltage-dependent channel properties, including altered voltage dependence of activation and inactivation, slower recovery from inactivation, and decreased channel availability during high-frequency depolarizations [3]. A notable finding is the enhancement of slow inactivation conferred by the p.Arg853Gln mutation, which is a major driver of the loss-of-function phenotype and may explain the later onset of symptoms associated with this variant [3].Clinically, patients with the p.Arg853Gln variant typically present with infantile spasms after 6 months of age, which is consistent with the loss-of-function nature of the variant [5]. This is in contrast to gain-of-function SCN2A variants, which are often associated with earlier onset of seizures. The p.Arg853Gln variant has been reported to be de novo in a significant number of cases, indicating that it arises spontaneously rather than being inherited [1]. However, there are also instances where the variant has been inherited from a parent with a history of epilepsy or febrile seizures [1].The clinical phenotype associated with the p.Arg853Gln variant is variable, with some patients experiencing severe seizures that are often refractory to antiepileptic medications [4]. This refractoriness to treatment may be due in part to the presence of gating pore currents, which are aberrant currents flowing through a pathogenic ion conduction pathway created by the mutation. These gating pore currents can lead to a chronic depolarization of the membrane potential, potentially contributing to the pathogenesis of seizures [4].In summary, the c.2558G>A p.Arg853Gln rs794727152 variant on the SCN2A gene is a pathogenic missense variant that results in a loss-of-function effect on the NaV1.2 channel, leading to a range of neurodevelopmental disorders with a predominant phenotype of late-onset developmental and epileptic encephalopathies. The variant's impact on neuronal excitability and response to treatment underscores the importance of understanding the functional consequences of SCN2A variants for the development of targeted therapies.

ゲノム変異c.2558G>A p.Arg853Gln（rs794727152）は、NaV1.2電位依存性ナトリウムチャネルをコードするSCN2A遺伝子上に位置しています。このチャネルは主に興奮性ニューロンで発現しており、活動電位の開始と伝播において重要な役割を果たし、神経の興奮性と通信に不可欠です。p.Arg853Gln変異は、発達性およびてんかん性脳症（DEE）や自閉症スペクトラム障害（ASD）を含むさまざまな神経発達障害と関連付けられています。このミスセンス変異は、NaV1.2チャネルの853番目の位置にあるアルギニンがグルタミンに置換される結果をもたらします。この位置はタンパク質のヘリカルリピートII領域内の高度に保存されたアミノ酸残基であり、その機能的重要性が示唆されています[2]。

機能的研究により、p.Arg853Gln変異がNaV1.2チャネルに対して機能喪失効果を引き起こすことが示されています。具体的には、この変異は活性化および不活性化の電圧依存性の変化、不活性化からの回復の遅延、高頻度脱分極中のチャネル利用可能性の低下など、時間および電圧依存的なチャネル特性の複数の欠陥により、チャネル機能全体の低下を引き起こします[3]。注目すべき発見として、p.Arg853Gln変異によって引き起こされる遅い不活性化の増強が挙げられます。これは機能喪失表現型の主な要因であり、この変異に関連する症状の発症が遅れる理由を説明する可能性があります[3]。

臨床的には、p.Arg853Gln変異を持つ患者は通常、生後6か月以降に乳児けいれんを発症します。これは、この変異の機能喪失的性質と一致しています[5]。これは、発作の発症がより早い時期に見られることが多い機能獲得型のSCN2A変異とは対照的です。p.Arg853Gln変異は、多くのケースで新生（de novo）であると報告されており、遺伝ではなく自然発生的に生じることを示しています[1]。しかし、親がてんかんや熱性けいれんの既往歴を持つ場合に、この変異が遺伝している例もあります[1]。

p.Arg853Gln変異に関連する臨床表現型は多様であり、一部の患者は重度の発作を経験し、抗てんかん薬に対してしばしば難治性を示します[4]。この治療抵抗性は、変異によって作られる病的なイオン伝導経路を通じて流れる異常な電流（ゲーティングポア電流）の存在に部分的に起因している可能性があります。これらのゲーティングポア電流は膜電位の慢性的な脱分極を引き起こし、発作の病態形成に寄与する可能性があります[4]。

まとめると、SCN2A遺伝子上のc.2558G>A p.Arg853Gln（rs794727152）変異は、NaV1.2チャネルに対して機能喪失効果をもたらす病原性ミスセンス変異であり、主に遅発性の発達性およびてんかん性脳症を特徴とするさまざまな神経発達障害を引き起こします。この変異が神経の興奮性および治療反応性に与える影響は、SCN2A変異の機能的影響を理解し、標的治療の開発における重要性を強調しています。
    
## References
- [1] Zeng Q et al. (2022). "SCN2A-Related Epilepsy: The Phenotypic Spectrum, Treatment and Prognosis." Frontiers in molecular neuroscience, 15() [PubMed](https://pubmed.ncbi.nlm.nih.gov/35431799/)
- [2] Crawford K et al. (2021). "Computational analysis of 10,860 phenotypic annotations in individuals with SCN2A-related disorders." Genetics in medicine : official journal of the American College of Medical Genetics, 23(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/33731876/)
- [3] Ganguly S et al. (2021). "Enhanced slow inactivation contributes to dysfunction of a recurrent SCN2A mutation associated with developmental and epileptic encephalopathy." The Journal of physiology, 599(18) [PubMed](https://pubmed.ncbi.nlm.nih.gov/34287911/)
- [4] Mason ER et al. (2019). "Resurgent and Gating Pore Currents Induced by De Novo SCN2A Epilepsy Mutations." eNeuro, 6(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/31558572/)
- [5] Mao M et al. (2024). "Distinctive In Vitro Phenotypes in iPSC-Derived Neurons From Patients With Gain- and Loss-of-Function SCN2A Developmental and Epileptic Encephalopathy." The Journal of neuroscience : the official journal of the Society for Neuroscience, 44(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38148154/)
- [6] Berecki G et al. (2018). "Dynamic action potential clamp predicts functional separation in mild familial and severe de novo forms of SCN2A epilepsy." Proceedings of the National Academy of Sciences of the United States of America, 115(24) [PubMed](https://pubmed.ncbi.nlm.nih.gov/29844171/)
- [7] Wolff M et al. (2017). "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders." Brain : a journal of neurology, 140(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/28379373/)
- [8] Jia L et al. (2024). "Variant-specific in vitro neuronal network phenotypes and drug sensitivity in SCN2A developmental and epileptic encephalopathy." Journal of neurochemistry, 168(12) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38544375/)
- [9] Eltokhi A et al. (2024). "Pathogenic gating pore current conducted by autism-related mutations in the Na(V)1.2 brain sodium channel." Proceedings of the National Academy of Sciences of the United States of America, 121(15) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38564633/)
- [10] Nisha Bhattarai et al. (2024). "Molecular dynamics simulations reveal molecular mechanisms for the gain and loss of function effects of four SCN2A variants" bioRxiv,  [PubMed](https://doi.org/10.1101/2024.02.19.580930)
- [11] Cestele S et al. (2001). "Neutralization of gating charges in domain II of the sodium channel alpha subunit enhances voltage-sensor trapping by a beta-scorpion toxin." The Journal of general physiology, 118(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/11524459/)
- [12] Hoischen A et al. (2014). "Prioritization of neurodevelopmental disease genes by discovery of new mutations." Nature neuroscience, 17(6) [PubMed](https://pubmed.ncbi.nlm.nih.gov/24866042/)
- [13] Howden SE et al. (2016). "A Cas9 Variant for Efficient Generation of Indel-Free Knockin or Gene-Corrected Human Pluripotent Stem Cells." Stem cell reports, 7(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/27499201/)
- [14] Adney SK et al. (2020). "Functional and pharmacological evaluation of a novel SCN2A variant linked to early-onset epilepsy." Annals of clinical and translational neurology, 7(9) [PubMed](https://pubmed.ncbi.nlm.nih.gov/32750235/)
- [15] Miao P et al. (2021). "Differential Functional Changes of Nav1.2 Channel Causing SCN2A-Related Epilepsy and Status Epilepticus During Slow Sleep." Frontiers in neurology, 12() [PubMed](https://pubmed.ncbi.nlm.nih.gov/34093402/)

    
## ClinVar Submissions
- **[RCV001265273](https://www.ncbi.nlm.nih.gov/clinvar/RCV001265273/)**: Complex neurodevelopmental disorder
- **[RCV000174944](https://www.ncbi.nlm.nih.gov/clinvar/RCV000174944/)**: not provided
- **[RCV000197677](https://www.ncbi.nlm.nih.gov/clinvar/RCV000197677/)**: Developmental and epileptic encephalopathy, 11
- **[RCV000515237](https://www.ncbi.nlm.nih.gov/clinvar/RCV000515237/)**: Seizures, benign familial infantile, 3 (and 1 more)
- **[RCV002035405](https://www.ncbi.nlm.nih.gov/clinvar/RCV002035405/)**: Seizures, benign familial infantile, 3 (and 1 more)
- **[RCV001847809](https://www.ncbi.nlm.nih.gov/clinvar/RCV001847809/)**: West syndrome

    